On April 23, 2024, the FTC announced the issuance of a final rule banning employers from entering into, enforcing, or attempting to enforce post-employment non-compete clauses with workers ...
The FTC is targeting over 300 patents filed by 10 pharma stocks that it alleges are using “junk patents” to protect their investments. Below are three drug stocks at risk from the expanded ...
The Federal Trade Commission is stepping up its crackdown on so-called "junk ... on," FTC Chair Lina Khan said. The agency sent letters to 10 companies, warning that their patent listings were ...
Boehringer Ingelheim, one of 10 companies sent a warning letter by the FTC disputing the accuracy of patent listings in the ... "By challenging junk patent filings, the FTC is fighting these ...
Over the course of the current administration, the Department of Justice’s (DOJ) Antitrust Division and the Federal Trade Commission (FTC) have piled up several losses in lawsuits against ...
On Monday, Piper Sandler adjusted its price target for FTC Solar Inc. (NASDAQ:FTCI), a solar tracking solutions provider, to $0.40 from the previous $0.40, while keeping a Neutral rating on the stock.
FTC’s latest action targets more than 300 Orange Book patent listings across 10 different companies, which brings the total to more than 400 patent listings across 14 companies and should send a ...
the FTC highlighted specifically its disputes of so-called “junk patent listings” for “blockbuster” weight loss medications. To date, the FTC’s Orange Book patent disputes have been ...
The FTC oversees consumer protections ... Faust: So with respect to these listings, which some people call "junk patents," it makes total sense when you're looking at something like some part ...
Novo Nordisk’s Ozempic is also among 20 branded drugs the FTC is targeting as it challenges more than 300 “junk patent listings” in the Food and Drug Administration’s registry of approved drugs, in an ...